Profile
AGRX ZTS HLN TAK TEVA VTRS
Company Name Agile Therapeutics, Inc. Zoetis Inc. Haleon plc Takeda Pharmaceutical Company Limited Teva Pharmaceutical Industries Limited Viatris Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic
Market Cap $10.43M $79.26B $42.82B $42.13B $18.71B $15.67B
Employees 0.02K 14.10K 25.41K 49.28K 37.00K 32.00K
CEO Mr. Alfred F. Altomari Ms. Kristin C. Peck Mr. Brian James McNamara Mr. Christophe Weber Mr. Richard D. Francis Mr. Scott Andrew Smith Ph.D.
Ratings
AGRX ZTS HLN TAK TEVA VTRS
Quant Rating Score 2 3 3 3 1 3
Quant Rating Sell Neutral Neutral Neutral Strong Sell Neutral
Trading
AGRX ZTS HLN TAK TEVA VTRS
Last Close $1.51 $175.67 $9.48 $13.29 $17.03 $13.13
High 52 $1.95 $199.94 $10.69 $15.08 $18.96 $13.53
Low 52 $0.27 $145.54 $8.01 $12.6 $10.44 $10.05
Price vs. 52 Week High -22.56 % -12.14 % -11.32 % -11.87 % -10.18 % -2.96 %
Price vs. 52 Week Low 459.26 % 20.7 % 18.35 % 5.48 % 63.12 % 30.65 %
Total Return
AGRX ZTS HLN TAK TEVA VTRS
1 Month Return 0 % -7.27 % -5.01 % -6.08 % -6.33 % 13.48 %
3 Month Return 3.64 % -3.95 % -3.95 % -11.04 % -6.07 % 12.03 %
6 Month Return 284.22 % 1.67 % 11.27 % 0.68 % 2.65 % 19.8 %
9 Month Return 52.19 % -6.75 % 13.81 % -9.84 % 31 % -0.98 %
YTD Return -22.56 % -10.99 % 15.19 % -6.87 % 63.12 % 21.24 %
1 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
AGRX ZTS HLN TAK TEVA VTRS
Dividend Yield Percentage (TTM) - 0.98 % 2.11 % 4.77 % - 3.66 %
Dividend Paid and Capex Coverage Ration (TTM) - 2.1 % - 1.29 % 5.06 % 2.39 %
Dividend Per Share (TTM) - 1.73 % 0.16 % 0.63 % - 0.48 %
Payout Ratio (TTM) - 31.44 % - 101.62 % - -65.15 %
Growth
AGRX ZTS HLN TAK TEVA VTRS
Asset Growth -27.99 % -4.28 % -2.18 % 8.25 % -1.2 % -4.67 %
Gross Profit Growth 162.23 % 3.7 % 5.85 % -16.6 % 9.64 % -0.9 %
Revenue Growth 80.02 % 5.74 % 4.09 % 5.87 % 6.16 % -5.14 %
Revenue 3 Year -48.64 % 31.98 % 13.9 % 33.13 % -6.92 % -35.32 %
Revenue 5 Year - 53.64 % 32.87 % 149.89 % -23.33 % -41.73 %
Revenue 10 Year - 103.1 % 32.87 % 154.38 % -40.82 % -26.57 %
EBIT Growth 52.01 % 6.27 % 37.26 % 7.34 % -84.52 % -52.55 %
Net Income Growth 43.08 % 10.88 % -1.04 % -54.56 % 76.24 % -97.37 %
Net Income 3 Yeari Growth Per Share 99.48 % 47.55 % -8.67 % -61.74 % 86.29 % 104.09 %
Net Income 5 Yeari Growth Per Share 99.42 % 71.94 % 59.66 % 62.27 % 76.28 % -93.3 %
Net Income 10 Yeari Growth Per Share 99.79 % 404.24 % 59.66 % 36.33 % -133.42 % -97.12 %
Operating Income Growth 52.01 % 6.27 % 37.26 % 7.34 % -84.52 % -52.55 %
Operating Cash Flow Growth (CFG) 73.36 % 23.06 % -16.48 % -34.47 % -13.96 % -5.18 %
Operating 3 Year CFG 99.6 % 14.12 % 22.08 % -36.76 % 10.09 % 13.84 %
Operating 5 Year CFG 99.55 % 37.69 % 118.54 % 139.61 % -48.98 % -48.37 %
Operating 10 Year CFG 99.85 % 274.61 % 118.54 % 335.67 % -67.94 % -16.8 %
EPS Growth 88.59 % 12.64 % - -54.92 % 76.42 % -97.08 %
EPS Diluted Growth 88.59 % 12.92 % - -54.86 % 76.42 % -97.08 %
Book Value Per Share 41.02 % 15.25 % 1.35 % 13.54 % -7.25 % -1.92 %
Share Holder 3 Year Equity Growth Per Share -100.65 % 36.7 % -36.6 % 40.38 % -26.74 % -55.34 %
Share Holder 5 Year Equity Growth Per Share -100.64 % 139.55 % -39.41 % 73.27 % -53.44 % -27.35 %
Share Holder 10 Year Equity Growth Per Share 99.95 % 476.36 % -39.41 % 197.1 % -74.76 % 128.81 %
Dividend Per Share Growth - 15.15 % -85.58 % 1.95 % - -0.06 %
Dividend 3 Year Growth Per Share - 87.76 % -83.69 % 1.19 % - -
Dividend 5 Year Growth Per Share - 198.29 % -66.42 % 146.94 % -100 % -
Dividend 10 Year Growth Per Share - 665.58 % -66.42 % 103.93 % -100 % -
Debt Growth -1.76 % -15.91 % -9.43 % 24.67 % -6.53 % -5.93 %
Free Cash Flow Growth 73.46 % 22.25 % -20.06 % -53.54 % -19.19 % -7.35 %
Updated On 31 Dec 2023 31 Dec 2023 31 Dec 2023 31 Mar 2024 31 Dec 2023 31 Dec 2023
Profitability
AGRX ZTS HLN TAK TEVA VTRS
Gross Profit Margin TTM 63.63 % 68.87 % 59.91 % 62.47 % 49.87 % 40.26 %
Return on Assets TTM -105.97 % 16.93 % 3.26 % 1.99 % -2.38 % -1.97 %
Return on Equity TTM 104.04 % 47.99 % 6.54 % 4.04 % -14.58 % -4.43 %
Return on Capital Employed TTM 120.33 % 26.64 % 7.25 % 5.27 % 7.66 % -0.71 %
Net Income Per EBT TTM 100 % 79.65 % 65.38 % 109.03 % 175.89 % 92.81 %
EBT Per Ebit TTM 116.98 % 90.51 % 82.66 % 41.38 % -26.34 % 359.67 %
EBIT Per Revenue TTM -62.85 % 36.83 % 17.88 % 14.14 % 12.76 % -1.76 %
Cash Flow To Debt Ratio TTM - 44.8 % - 17.01 % 13 % 13.05 %
Receivables Turnover TTM 4.74 6.49 5.27 6.3 4.85 3.81
Payables Turnover TTM 0.47 7.05 1.25 4.13 3.55 7.23
Inventory Turnover TTM 1.35 1.18 3.09 1.41 2.13 2.2
Fixed Asset Turnover TTM 7648.23 % 259.93 % 604.62 % 240.84 % 278.05 % 561.67 %
Asset Turnover TTM 144.14 % 63.75 % 33.71 % 31.2 % 40.19 % 33.6 %
Operating Cash Flow Per Share TTM -0.25 6.5 - 545.34 2.18 1.93
Free Cash Flow Per Share TTM -0.25 5.1 - 309.43 1.75 1.6
Cash Per Share TTM 41.54 % 378.45 % 5.72 % 57513.46 % 292.94 % 157.41 %
Operating Cash Flow Sales Ratio TTM -7.91 % 32.18 % - 18.9 % 14.71 % 15.29 %
Free Cash Flow Operating Cash Flow Ratio TTM 100 % 78.37 % - 56.74 % 80.23 % 83.19 %
Cash Flow Coverage Ratios TTM - 44.8 % - 17.01 % 13 % 13.05 %
Price To Free Cash Flows Ratio TTM -6.11 34.34 - 13.34 9.45 8.19
Price To Operating Cash Flows Ratio TTM -6.07 27.02 - 3.76 7.82 6.81
Price Cash Flow Ratio TTM -6.07 27.02 - 3.76 7.82 6.81
Income Statement (TTM)
AGRX ZTS HLN TAK TEVA VTRS
Revenue $0.02B $8.54B $11.3B $4263.76B $15.85B $15.43B
Gross Profit $0.01B $5.83B $6.96B $2321.31B $7.65B $6.44B
Gross Profit Ratio 54.18% 68.28% 61.6% 54.44% 48.25% 41.74%
EBITDA $-0.02B $3.69B $2.35B $900.33B $4.33B $3.52B
Net Income $-0.01B $2.34B $1.05B $144.07B $-0.56B $0.05B
EPS Diluted -6.71 5.07 0.11 91.16 -0.5 0.05
Balance Sheet (MRQ)
AGRX ZTS HLN TAK TEVA VTRS
Long Term Debt $0B $6.75B $8.95B $5029.93B $18.48B $16.35B
Total Liabilities $0.03B $9.3B $17.33B $7834.79B $35.35B $27.22B
Total Equity $-0.02B $4.99B $16.73B $7274.01B $8.13B $20.47B
Total Investments $0B $0.02B $0.07B $683.22B $0.01B $1.33B
Total Debt $0B $6.76B $9.46B $5463.39B $20.15B $18.37B
Total Assets $0.01B $14.29B $34.06B $15108.79B $43.48B $47.69B
Cash Flow Statement (TTM)
AGRX ZTS HLN TAK TEVA VTRS
Net Income $-0.01B $2.34B $1.05B $144.07B $-0.62B $0.05B
Inventory $-0B $-0.36B $-0.13B $-115.74B $0B $-0.61B
Dividends Paid $0B $-0.69B $-0.39B $-287.19B $0B $-0.58B
Operating Cash Flow $-0.01B $2.35B $1.72B $640.32B $1.37B $2.8B
Capital Expenditure $0B $-0.73B $-0.34B $-480.73B $-0.53B $-0.47B
Related Stocks
Ticker Name Price
ACB Aurora Cannabis Inc. 4.24
ACOR Acorda Therapeutics, Inc. 0.661
ACRX AcelRx Pharmaceuticals, Inc. 0.86
ADMP Adamis Pharmaceuticals Corporation 0.775
ADMS Adamas Pharmaceuticals, Inc. 8.22
AERI Aerie Pharmaceuticals, Inc. 15.25
AKAN Akanda Corp. 1.37
ALIM Alimera Sciences, Inc. 5.54
ALVO Alvotech 12.42
ALVOW Alvotech 3.4
AMPH Amphastar Pharmaceuticals, Inc. 44.09
AMRX Amneal Pharmaceuticals, Inc. 8.41
AMYT Amryt Pharma plc 14.7
ANIP ANI Pharmaceuticals, Inc. 55.1
AQST Aquestive Therapeutics, Inc. 4.735
ASRT Assertio Holdings, Inc. 0.95
ATNX Athenex, Inc. 0.2031
AVDL Avadel Pharmaceuticals plc 10.75
AYTU Aytu BioPharma, Inc. 1.49
BDSI BioDelivery Sciences International, Inc. 5.59
ETFs With Exposure to AGRX
Ticker ETF Name Weight Percentage Price
ITOT iShares Core S&P Total U.S. Stock Market ETF 0 130.17
VXF Vanguard Extended Market Index Fund 0 196.7
VQNPX Vanguard Growth and Income Fund 0 69.53
VGIAX Vanguard Quantitative Funds - Vanguard Growth and Income Fund 0 113.5
VIEIX Vanguard Extended Market Index Fund Institutional Shares 0 149.17
VEXAX Vanguard Extended Market Index Fd Admiral Shs 0 149.17
JKK iShares Morningstar Small-Cap Growth ETF 0 307.42
VEMPX Vanguard Extended Market Index InstlPlus 0 368.12
Unlock